Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,541.89
(
-0.98%
)
US TECH 100
23,352.40
(
-1.55%
)
Dow Jones
45,796.94
(
-0.49%
)
Brent Oil
106.97
(
2.43%
)
Bitcoin
69,954.01
(
0.08%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ronpopeil post# 169228

Sunday, 11/03/2013 12:35:13 PM

Sunday, November 03, 2013 12:35:13 PM

Post# of 257262
ENTA—Nothing wrong with those phase-2 data from the PEARL-1 study! In the treatment-naïve GT1b cohort, SVR12 was 95% (20/22) on an ITT basis (and it would’ve been 100% excluding the 2 patients lost to follow-up). In the treatment-experienced GT1b cohort, SVR12 was 90% (36/40), also on an ITT basis.

Reminder: The PEARL-1 study is a phase-2 testing (among other things) the 2-DAA regimen of ABT-450 + ABT-267—without ABT-333 or ribavirin—in GT1b patients. This is the regimen ABBV/ENTA are taken into phase-3 for GT1b approval in Japan.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today